Neurology · AntidepressantRegulatory Approvalcompetitivenear-term

FDA Approves ANDA for Bupropion Hydrochloride by Yichang Humanwell

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 12:32:50 PM

Assessment confidence: 70% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Yichang Humanwell's ANDA for Bupropion Hydrochloride introduces a new competitor in the antidepressant market, which could impact pricing and market share for existing products. Portfolio teams must evaluate the competitive landscape and adjust strategies accordingly. Regulatory context from FDA (FDA AP — BUPROPION HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new entrant on market share and pricing strategies for existing products. The strongest clinical anchor is A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Antidepressant, 8 regulatory and 4 competitive items passed relevance filtering for Bupropion Hydrochloride.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — BUPROPION HYDROCHLORIDE (ORIG) (FDA). Entity match (bupropion hydrochloride); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not suggest immediate changes to regulatory frameworks for existing products.

Key Opportunities

The entry of Yichang Humanwell could lead to increased competition, potentially affecting revenue and market positioning for current players in the antidepressant sector.
Upside for Bupropion Hydrochloride may improve if Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Bupropion Hydrochloride may improve if Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this new entrant on market share and pricing strategies for existing products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and any subsequent pricing strategies from Yichang Humanwell.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (bupropion hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (bupropion hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SOTALOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effects of Eccentric Compared to Standard Strength Training in Primary Spinal Cord Injury Rehabilitation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment

Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Bupropion Hydrochloride

Commercial impact

medium

The entry of Yichang Humanwell could lead to increased competition, potentially affecting revenue and market positioning for current players in the antidepressant sector.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not suggest immediate changes to regulatory frameworks for existing products.

What to watch

Monitor market entry timelines and any subsequent pricing strategies from Yichang Humanwell.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.